Vosoritide

伏索利肽

Report date: 2026/05/12 20:00:17

Base Information

Drug NameVosoritide
Drug Alias NameModified C-natriuretic peptide (BioMarin Pharmaceutical)Modified recombinant human C-type natriuretic peptide (BioMarin Pharmaceutical)ProCNP38 (BioMarin Pharmaceutical)VOXZOGOVoxzogo +[6] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionAtrial natriuretic peptide receptor type B agonists
TargetsAtrial natriuretic peptide receptor type B
Therapy Area/IndicationsIdiopathic short statureMucopolysaccharidosis VIMucopolysaccharidosis IV +[5] 
Global Approved IndicationsAchondroplasia
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2021/08/26
Country/TerritoryCanadaUnited StatesTurkey +[13] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaNDA/BLA
Originator CompaniesBiomarin Pharmaceutical Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoBiomarin Pharmaceutical IncBiomarin International Ltd
Inactive CompaniesN/A
Active IndicationsIdiopathic short statureMucopolysaccharidosis VIMucopolysaccharidosis IV +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeM05BX
Related LinksWikipediaDrugBankKEGG